AUG 6·SEC EDGARLow
Ford Alfred J Jr sold $151K of KMTS
Ford Alfred J Jr (Chief Commercial Officer) sold 6,275 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $24.09 ($0.15M total) on 2026-08-04.
StockNASDAQ · US · USDHealthcare · Medical Instruments & Supplies
$KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Price · $KMTSvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $KMTS in the last 7 days.
Top stories · $KMTSMore →
AUG 6·SEC EDGAR
Webster Brian Daniel sold $1.3M of KMTS
Webster Brian Daniel (See Remarks) sold 51,900 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $24.52 ($24.47–$25.98, $1.27M total) across 3 trades on 2026-08-04.
AUG 3·SEC EDGAR
Moran Timothy P. sold $348K of KMTS
Moran Timothy P. (Chief Business Officer) sold 15,256 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $22.83 ($22.61–$23.76, $0.35M total) across 3 trades over 2026-07-30 to 2026-08-03.
KMTS sentiment & insider activity
Recent KMTS coverage spans insider activity, earnings and corporate actions.
In the last 30 days, KMTS insiders filed 25 SEC Form 4 transactions — no purchases and 25 sales ($4.6M). The most active reporter was Webster Brian Daniel, See Remarks, with 9 filings. 20% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving KMTS
This is a routine insider open-market sale with no 10b5-1 plan disclosed, which can modestly affect near-term sentiment but is not a fundamental catalyst.
This is a routine insider sale under a Form 4, with no stated 10b5-1 plan, but it does not disclose new company fundamentals.
The filing discloses an insider open-market sale by the company’s Chief Business Officer, which can modestly affect near-term sentiment but is not a fundamental update by itself.
This is a routine insider sale disclosure, not a fundamental company update, but it can slightly affect near-term sentiment and positioning.
This is a routine insider sale with no 10b5-1 plan disclosed, which can modestly affect near-term sentiment but is not a fundamental update.
alphai scores every news story that mentions KMTS with an AI model for sentiment and relevance, and aggregates insider trades from KESTRA MEDICAL TECHNOLOGIES, LTD.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $KMTS
Score
Ford Alfred J Jr sold $151K of KMTS
Ford Alfred J Jr (Chief Commercial Officer) sold 6,275 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $24.09 ($0.15M total) on 2026-08-04.
2 min readWebster Brian Daniel sold $1.3M of KMTS
Webster Brian Daniel (See Remarks) sold 51,900 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $24.52 ($24.47–$25.98, $1.27M total) across 3 trades on 2026-08-04.
2 min readMoran Timothy P. sold $348K of KMTS
Moran Timothy P. (Chief Business Officer) sold 15,256 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $22.83 ($22.61–$23.76, $0.35M total) across 3 trades over 2026-07-30 to 2026-08-03.
1 min readFord Alfred J Jr sold $643K of KMTS
Ford Alfred J Jr (Chief Commercial Officer) sold 27,632 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $23.25 ($22.61–$23.90, $0.64M total) across 3 trades over 2026-07-30 to 2026-08-03.
2 min readMahboob Vaseem sold $418K of KMTS
Mahboob Vaseem (Chief Financial Officer) sold 18,188 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $22.99 ($22.61–$23.80, $0.42M total) across 3 trades over 2026-07-30 to 2026-08-03.
1 min readUmberger Traci S sold $513K of KMTS
Umberger Traci S (See Remarks) sold 22,229 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $23.07 ($22.60–$23.86, $0.51M total) across 3 trades over 2026-07-30 to 2026-08-03.
2 min readWebster Brian Daniel sold $692K of KMTS
Webster Brian Daniel (See Remarks) sold 29,822 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $23.21 ($22.60–$23.92, $0.69M total) across 3 trades over 2026-07-30 to 2026-08-03.
2 min readKestra Medical Technologies Q4 Earnings Call Highlights
Kestra Medical Technologies (NASDAQ:KMTS) reported a Q4 GAAP net loss of $38.8 million and adjusted EBITDA loss of $26.7 million. CFO Vaseem Mahboob said gross margin should rise steadily and reiterated confidence in gross margins above 70% over the next few years. The company guided FY2027 revenue to $137 million, up 44% from FY2026, and added a $200 million term loan facility.
6 min read
Kestra Secures $200M Non-Dilutive Financial To Strengthen Balance Sheet And Fuel Growth
Kestra Medical Technologies (KMTS) said it secured a five-year, up to $200M non-dilutive term loan facility managed by Pharmakon Advisors. A $75M tranche closed, retiring part of its $45M loan and covering fees. Remaining tranches total $125M with revenue and acquisition conditions. The loan has 48 months interest-only at 3-month SOFR plus 5.5% (3.25% floor).
4 min read
Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue
Kestra Medical Technologies (KMTS) reported Q4 2026 call highlights. CFO Vaseem Mahboob said fiscal 2027 guidance targets $137 million revenue, driven by prescription volume growth, in-network mix, revenue cycle management improvements, and field expansion, with 44% growth. CEO Brian Webster discussed WCD guideline support, share gains, adding ~40 reps, and refinancing to cut cost of capital by 24% while keeping an M&A option open.
4 min read